Title:
SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/122316
Kind Code:
A3
Abstract:
The present disclosure relates to the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are splice switch oligonucleotide (SSO) molecules for targeting β-catenin, compositions containing the same, and uses thereof for treating or preventing β-catenin associated diseases or disorders. In particular, the present invention is in the field of SSO molecules that targets β-catenin for treatment of cancer.
Inventors:
HONG JIN (US)
BEIGELMAN LEONID (US)
BHATTACHARYA ANEERBAN (US)
ELTEPU LAXMAN (US)
HUANG VERA (US)
BEIGELMAN LEONID (US)
BHATTACHARYA ANEERBAN (US)
ELTEPU LAXMAN (US)
HUANG VERA (US)
Application Number:
PCT/US2022/053895
Publication Date:
August 03, 2023
Filing Date:
December 22, 2022
Export Citation:
Assignee:
ALIGOS THERAPEUTICS INC (US)
International Classes:
C12N15/113; A61K31/712; A61K31/7125; A61P35/00
Domestic Patent References:
| WO2021207641A1 | 2021-10-14 | |||
| WO2019079472A1 | 2019-04-25 | |||
| WO2017160983A1 | 2017-09-21 |
Other References:
VONBRÜLL MATTHIAS ET AL: "A Dominant Negative Antisense Approach Targeting [beta]-Catenin", MOLECULAR BIOTECHNOLOGY, vol. 60, no. 5, 9 March 2018 (2018-03-09), pages 339 - 349, XP036489407, ISSN: 1073-6085, [retrieved on 20180309], DOI: 10.1007/S12033-018-0058-7
GREEN D W ET AL: "Beta-Catenin antisense treatment decreases beta-Catenin expression andn tumor growth rate in colon carcinoma xenografts", JOURNAL OF SURGICAL RESEARCH, vol. 101, no. 1, 1 November 2001 (2001-11-01), pages 16 - 20, XP002512179, ISSN: 0022-4804, DOI: 10.1006/JSRE.2001.6241
SUMITHRA B ET AL: "Alternative splicing within the Wnt signaling pathway: role in cancer development", CELLULAR ONCOLOGY, vol. 39, no. 1, 13 January 2016 (2016-01-13), pages 1 - 13, XP035736853, ISSN: 2211-3428, [retrieved on 20160113], DOI: 10.1007/S13402-015-0266-0
GREEN D W ET AL: "Beta-Catenin antisense treatment decreases beta-Catenin expression andn tumor growth rate in colon carcinoma xenografts", JOURNAL OF SURGICAL RESEARCH, vol. 101, no. 1, 1 November 2001 (2001-11-01), pages 16 - 20, XP002512179, ISSN: 0022-4804, DOI: 10.1006/JSRE.2001.6241
SUMITHRA B ET AL: "Alternative splicing within the Wnt signaling pathway: role in cancer development", CELLULAR ONCOLOGY, vol. 39, no. 1, 13 January 2016 (2016-01-13), pages 1 - 13, XP035736853, ISSN: 2211-3428, [retrieved on 20160113], DOI: 10.1007/S13402-015-0266-0
Attorney, Agent or Firm:
SCHORR, Kristel et al. (US)
Download PDF: